Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

Annals of Hematology

Volumn 91, Issue 6, 2012, Pages 923-929

  Faber, Edgar ^a   Friedecký, David ^a   Mičová, Kateřina ^a   Rožmanová, Šárka ^a   Divoká, Martina ^a   Jarošová, Marie ^a   Indrák, Karel ^a   Adam, Tomáš ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Chronic myeloid leukemia; Imatinib; Plasma levels; Treatment response

Indexed keywords

ALPHA INTERFERON; IMATINIB;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHEMATOLOGICAL TOXICITY; OBSERVER VARIATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BLOOD CHEMICAL ANALYSIS; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862686680     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1394-x     Document Type: Article

References (19)

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041-6051
2. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, for the IRIS (International Randomized Interferon vs. STI571) Study Group et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022-4028
3. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M-A et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 109:3496-3499 (Pubitemid 46572540)
4. Singh N, Kumar L, Meena R, Velpandian T (2009) Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 65:545-549
5. Faber E, Friedecky D, Tomkova J, Rozmanova S, Rohon P, Skoumalova I et al (2008) Imatinib plasma levels correlate with molecular response in CML patients. Haematologica 93 (suppl 1):219-220, Abstract 0543
6. Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ et al (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Res 33:271-275
7. Davies A, Hayes AK, Giannoudis A, Lucas CM, Knight K, Watmough SJ et al (2009) Astudy of plasma levels of imatinib and its bioactive metabolite CGP-74588 reveals no correlation with subsequent clinical outcome in imatinib-treated chronicmyeloid leukemia. Haematologica 94(suppl 2):259, Abstract 0637
8. Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon F-X (2009) Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 23:1537-1544
9. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simmonsson B, Appelbaum F et al (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820 (Pubitemid 44394987)
10. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799 (Pubitemid 14141296)
11. Faber E, Naušová J, Jarošová M, Egorin MJ, Holzerová M, Rožmanová Š et al (2006) Intermittent dosage of imatinib mesylate in CML patients with history of significant hematologic toxicity after standard dosing. Leuk Lymphoma 47:1082-1090 (Pubitemid 44102971)
12. The Italian Cooperative Study Group on ChronicMyeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825
13. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159 (Pubitemid 17064313)
14. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al (2003) Standardization and quality control studies of "real-time" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe against cancer program. Leukemia 17:2318-2357 (Pubitemid 38072573)
15. Mičová K, Friedecký D, Faber E, Polý nková A, Adam T (2010) Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clin Chim Acta 411:1957-1962
16. Osborn MP, White DL, Saunders VA, Cambareri B, Branford S, Menelaou A, et al (2009) Early dose-escalation in chronic myeloid leukaemia patients with low plasma imatinib levels leads to equivalent BCR-ABL values and drug levels at 6 months to those with optimal drug levels: first analysis from the TIDEL II trial of denovo patients treated with 600 mg imatinib. Blood 114(22); Abstract 1131
17. Faber E, Friedecký D, Mičová K, Divoká M, Katrincsáková B, Rožmanová Š et al (2010) Imatinib dose escalation in two patients with chronic myeloid leukemia with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response lead to the achievement of higher plasma levels and major molecular response. Int J Hematol 91:897-902
18. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K et al (2010) Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 101:2186-2192
19. Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T et al (2009) Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 89:319-325